Volume 2, Issue 1 (Autumn 2009)                   Iranian Journal of Blood and Cancer 2009, 2(1): 7-10 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pediatric Meduloblastoma and the Prognostic Value of MIB-1 Proliferative Factor. Iranian Journal of Blood and Cancer 2009; 2 (1) :7-10
URL: http://ijbc.ir/article-1-163-en.html
Abstract:   (13570 Views)

Background: Medulloblastoma is the most common malignant brain tumor in children. The important factors in predicting survival are the extent of disease, proliferation index of the tumor cells, histopathologic class and the age at diagnosis. The percentage of Ki-67 positive cells reflects the proliferation  of the cells and is one of the critical factors which determine the growth of the tumor. Monoclonal MIB-1 antibody can be targeted against recombinant Ki-67 and then demonstrated by immunohistochemical methods. 

Materials and Methods: Formalin-fixed, paraffin-embedded tissue of 18 pediatric patients with medulloblastoma at

Mofid

Children

Hospital between January 2003 and December 2008 were used to perform Ki-67 (MIB-1) immunohistochemical analysis. Proliferative labeling index (LI ) was scored in the tumor cells to determine the extent of proliferation.

Results: The mean±SD of MIB-1 LI index was 53%±21% (range 25% to 85%). Kaplan–Meier curves showed that patients with MIB-1 LI <40% had higher 5-year survival than patients with MIB-1 LI> 40%  (p=0.04). This difference remained statistically significant in Cox regression analysis.

Conclusion: We suggest that MIB-1 LI is helpful as a prognostic factor in predicting survival of patients with pediatric medulloblastoma.

Full-Text [PDF 237 kb]   (5057 Downloads)    
: Original Article | Subject: Pediatric Hematology & Oncology
Received: 2011/02/20 | Published: 2009/10/15

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb